Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ABC Fine Wine & SpiritsABC Fine Wine & Spirits Named Official Celebration Partner of the Tampa Bay LightningIconic Florida brands team up to give fans more reasons to celebrate throughout the season — ABC Fine Wine & Spirits, Florida's largest family-owned wine and spirits retailer, is proud to announce a new partnership with the Tampa Bay Lightning,...
- Assessment of Europe's Food Waste Recycling Market 2026-2036 Featuring Veolia Environnement, SUEZ Group, Biffa Group, Renewi, BTS Biogas and Other Key PlayersCompanies: Veolia"Europe Food Waste Recycling Market Size, Share & Trends Analysis - Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering. According to the research report, the Europe food waste recycling market is projected to reach $5.91 billion by 2036, at a CAGR of 13.5% during the forecast period 2026-2036. The report provides an in-depth analysis of the Europe food waste recycling market, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by stringent EU waste management regulations and mandatory bio-waste separation policies, rising demand for renewable energy and organic fertilizers, the expanding circular economy agenda across European nations, and increasing adoption of advanced recycling technologies such as anaerobic digestion. Moreover, growing investment in biorefinery infrastructure, the surging demand for bioplastics and bio-based materials, and digital transformation of waste management operations are expected to support the market's growth. However, high upfront capital requirements for recycling infrastructure, feedstock contamination issues, and fragmented regulatory frameworks across EU member states may restrain market growth. The key players operating in the Europe food waste recycling market are Veolia Environnement SA (France), SUEZ Group (France), Biffa Group Limited (U.K.), Renewi plc (Netherlands/U.K.), BTS Biogas Srl/GmbH (Italy), Anaergia Inc. (Canada), WELTEC BIOPOWER GmbH (Germany), PreZero International GmbH (Germany), FCC Environment Ltd (U.K.), Remondis SE & Co. KG (Germany), Biogen (U.K.), ReFood GmbH & Co. KG (Germany), Masias Recycling (Spain), Ecofast Italia (Italy), and others. The Europe food waste recycling market is segmented by byproduct type (organic fertilizers, animal feed, biofuels, bioplastics, and other biochemicals), feedstock source (household food waste, food processing industry, food service and hospitality, retail and supermarkets, and agricultural residues), recycling method (anaerobic digestion, composting, pelletization, fermentation, and other technologies), end-use application, and country. The study also evaluates industry competitors and analyzes the market at the country level. Based on byproduct type, the organic fertilizers segment is expected to account for the largest share of the Europe food waste recycling market in 2026. This segment leads primarily due to the continent's strong commitment to sustainable agriculture, the EU Farm to Fork Strategy targeting 25% organic farmland by 2030, and reduced reliance on chemical fertilizers across European agricultural operations. Food waste-derived compost and digestate fertilizers provide nutrient-rich alternatives to synthetic inputs and are increasingly sought after by farmers and gardeners throughout Europe. The growing emphasis on soil health, carbon sequestration, and biodiversity restoration further underpins demand for organic fertilizers derived from recycled food waste. Regulatory frameworks mandating separate bio-waste collection at the household level ensure a consistent and high-quality feedstock base for organic fertilizer production. Additionally, long-term offtake agreements between major retailers such as Tesco, Carrefour, and REWE with recycling operators provide supply chain certainty and support the development of large-scale composting and digestion facilities across the region. Based on recycling method, the anaerobic digestion segment is expected to account for the largest share of the Europe food waste recycling market in 2026. Anaerobic digestion dominates the European food waste recycling market with a 30-40% share, driven by its ability to simultaneously generate two high-value outputs: renewable biogas (or biomethane) for energy use and nutrient-rich digestate for agricultural applications. This dual-output capability makes anaerobic digestion economically attractive and aligns with both the EU's renewable energy targets under RED III and its circular economy objectives. The technology processes over 35 million tonnes of food waste annually across Europe, generating renewable energy sufficient to power approximately 4 million homes. Countries such as Germany, France, and the Netherlands are leading the deployment of large-scale anaerobic digestion plants, with Germany's national biomethane strategy targeting 10% of its gas grid supplied by food waste and agricultural residues by 2030. Advances in biogas upgrading, decentralized digestion systems, and improved methane yields are expanding the accessibility of this technology to smaller municipalities and rural regions, reinforcing the segment's market dominance. Based on feedstock source, the food processing industry segment is expected to account for the largest share of the Europe food waste recycling market in 2026. The food processing industry dominates feedstock supply with a 40-45% share, supported by consistent and large-volume waste streams from meat, dairy, bakery, and beverage processing operations. Unlike household food waste, which can be subject to contamination from non-organic materials, food processing waste is typically well-sorted and suitable for high-efficiency recycling operations. Producer responsibility schemes and long-term recycling contracts signed between food processors and waste management companies ensure stable feedstock supplies for recycling facilities across Europe. Increasing regulatory pressure on food manufacturers to divert organic waste from landfills, combined with the economic incentive of cost-effective waste disposal through recycling partnerships, is driving this segment's dominance. Innovations in valorization technologies that extract bio-based chemicals, enzymes, and specialty ingredients from food processing residues are also opening new revenue streams and further incentivizing industrial participation in food waste recycling. A thorough geographic analysis of the industry gives detailed insights across key European countries. Germany is expected to account for the largest share of the Europe food waste recycling market in 2026. Germany's leadership in the European food waste recycling market reflects the country's world-renowned waste management infrastructure, mature regulatory frameworks, and strong circular economy culture. Germany's national biomethane strategy, backed by a EUR 3 billion subsidy program, is accelerating the upgrading of anaerobic digestion facilities and driving large-scale food waste valorization. Major waste management companies including Remondis, Veolia, and SUEZ operate extensive processing networks throughout Germany, offering comprehensive services spanning collection, anaerobic digestion, composting, and bio-based product marketing. Western Europe overall leads the regional market, supported by well-established waste collection systems, advanced processing infrastructure, and strong regulatory compliance. In contrast, Eastern Europe is the fastest-growing sub-region, with Poland projected to expand at a 14.4% CAGR, driven by EU funding and rapid infrastructure development. Italy stands out for its circular economy approach, processing 7.1 million tonnes of organic waste annually through over 400 facilities, while France is growing at a 10.6% CAGR, supported by strict anti-waste legislation and a national pact involving over 500 companies committed to halving food waste by 2030. Key Questions Answered in the Report:
- ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment OptionHONG KONG, Sept 21, 2026 - Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”. Everest Medicines acquired the rights to develop, manufacture, and commercialize CARDAMYST(R) (etripamil), a treatment for acute PSVT episodes, in Greater China (including Mainland China, Hong Kong, Macao and Taiwan) in March 2026. CARDAMYST(R) (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST(R) is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. The drug was approved by the National Medical Products Administration (NMPA) of China in September 2026, for the conversion of acute symptomatic episodes of paroxysmal PSVT to sinus rhythm in adults. According to clinical data, treatment effects can be observed as early as five minutes after administration, with 64% of patients achieving conversion to sinus rhythm within 30 minutes and a median time to conversion of 17 minutes. CARDAMYST(R) was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. Positioned as an on-demand treatment that enables patients to take control of their heart rhythm, CARDAMYST(R) empowers patients with PSVT to better manage their condition and their lives. It has the potential to transform the treatment paradigm for acute PSVT episodes from passive emergency care in hospitals to proactive self-management by patients, helping to alleviate anxiety during episodes, reduce emergency department visits and disease burden, and further improve long-term disease management and quality of life. Research presented at ESC Congress 2026 shows that PSVT is a chronic condition that continues to impact patients’ quality of life, rather than simply an occasional acute emergency. Patients with PSVT experience a substantial burden between episodes, with negative impacts on anxiety, daily activities, sleep, and work. Therefore, beyond acute treatment and subsequent catheter ablation, ensuring timely and convenient treatment during an episode is also an important aspect of PSVT management. For patients experiencing recurrent PSVT episodes, further data from studies of CARDAMYST(R) provide additional clinical support. The NODE-302 study evaluated patients with recurrent PSVT episodes during long-term follow-up. Across a total of 188 episodes, the overall conversion rate within 30 minutes was 60.2%, with a median time to conversion of 15.5 minutes and a cumulative conversion rate of 75.1% within 60 minutes. The conversion rate showed a numerical upward trend across multiple episodes. A patient’s response to the first episode was predictive of the response to subsequent episodes, with no evidence of diminished response with repeated use. In a patient-reported outcomes (PRO) analysis from the NODE-303 study, CARDAMYST(R) not only converted heart rhythm but also helped alleviate feelings of a racing or pounding heart and ease anxiety, with patients reporting sustained reductions from baseline in anxiety and stress related to future PSVT episodes. CARDAMYST(R) addresses the critical unmet need for acute self-treatment during PSVT episodes. By reducing the sense of losing control, it shifts the treatment focus from mere disease control to enhancing the overall patient experience. In December 2025, CARDAMYST(R) was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting PSVT to sinus rhythm in adults. CARDAMYST(R) is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. An estimated 3 to 6 million people in China are living with PSVT. Research presented at ESC Congress 2026 further highlights the quality-of-life burden experienced by patients between episodes, while CARDAMYST(R) offers an out-of-hospital, self-administered treatment option for acute episodes. As Everest Medicines’ first approved innovative therapy in the cardiovascular disease field, CARDAMYST(R) complements the Company’s existing portfolio and has the potential to benefit more than 12 million patients in China, including those with PSVT and atrial fibrillation with AFib-RVR.
- ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment OptionHONG KONG, Sept 21, 2026 - Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”. Everest Medicines acquired the rights to develop, manufacture, and commercialize CARDAMYST(R) (etripamil), a treatment for acute PSVT episodes, in Greater China (including Mainland China, Hong Kong, Macao and Taiwan) in March 2026. CARDAMYST(R) (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST(R) is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. The drug was approved by the National Medical Products Administration (NMPA) of China in September 2026, for the conversion of acute symptomatic episodes of paroxysmal PSVT to sinus rhythm in adults. According to clinical data, treatment effects can be observed as early as five minutes after administration, with 64% of patients achieving conversion to sinus rhythm within 30 minutes and a median time to conversion of 17 minutes. CARDAMYST(R) was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. Positioned as an on-demand treatment that enables patients to take control of their heart rhythm, CARDAMYST(R) empowers patients with PSVT to better manage their condition and their lives. It has the potential to transform the treatment paradigm for acute PSVT episodes from passive emergency care in hospitals to proactive self-management by patients, helping to alleviate anxiety during episodes, reduce emergency department visits and disease burden, and further improve long-term disease management and quality of life. Research presented at ESC Congress 2026 shows that PSVT is a chronic condition that continues to impact patients’ quality of life, rather than simply an occasional acute emergency. Patients with PSVT experience a substantial burden between episodes, with negative impacts on anxiety, daily activities, sleep, and work. Therefore, beyond acute treatment and subsequent catheter ablation, ensuring timely and convenient treatment during an episode is also an important aspect of PSVT management. For patients experiencing recurrent PSVT episodes, further data from studies of CARDAMYST(R) provide additional clinical support. The NODE-302 study evaluated patients with recurrent PSVT episodes during long-term follow-up. Across a total of 188 episodes, the overall conversion rate within 30 minutes was 60.2%, with a median time to conversion of 15.5 minutes and a cumulative conversion rate of 75.1% within 60 minutes. The conversion rate showed a numerical upward trend across multiple episodes. A patient’s response to the first episode was predictive of the response to subsequent episodes, with no evidence of diminished response with repeated use. In a patient-reported outcomes (PRO) analysis from the NODE-303 study, CARDAMYST(R) not only converted heart rhythm but also helped alleviate feelings of a racing or pounding heart and ease anxiety, with patients reporting sustained reductions from baseline in anxiety and stress related to future PSVT episodes. CARDAMYST(R) addresses the critical unmet need for acute self-treatment during PSVT episodes. By reducing the sense of losing control, it shifts the treatment focus from mere disease control to enhancing the overall patient experience. In December 2025, CARDAMYST(R) was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting PSVT to sinus rhythm in adults. CARDAMYST(R) is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. An estimated 3 to 6 million people in China are living with PSVT. Research presented at ESC Congress 2026 further highlights the quality-of-life burden experienced by patients between episodes, while CARDAMYST(R) offers an out-of-hospital, self-administered treatment option for acute episodes. As Everest Medicines’ first approved innovative therapy in the cardiovascular disease field, CARDAMYST(R) complements the Company’s existing portfolio and has the potential to benefit more than 12 million patients in China, including those with PSVT and atrial fibrillation with AFib-RVR.
- 2LC Graphics Helps Houston Restaurants and Bars Put Their Logo on Staff Uniforms and Table ItemsLooking for dependable embroidery services in Houston.
- Why More Bakersfield Families Are Choosing All-In-One Birthday Party DestinationsWhy Central Valley families choose all-in-one birthday party destinations that combine food, games, and a private party room in one Bakersfield visit.
- SMPL FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages The Simply Good Foods Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – SMPLWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Simply Good Foods Company (NASDAQ: SMPL) between October 24, 2024 and April 8, 2026, inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
- Simply Good Foods Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Simply Good Foods Company - SMPLClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Simply Good Foods Company ("Simply Good" or the...
- Kung Fu Thai & Chinese Restaurant in Las Vegas Introduces Pepsi Beverages to Complement Its CuisineLAS VEGAS, NV - September 18, 2026 -
- Kessler Topaz Meltzer & Check, LLPThe Simply Good Foods Company (SMPL) Investors: October 13, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLPDid you buy SMPL common stock between October 24, 2024 and April 8, 2026? Affected SMPL Investor Summary Who: The Simply Good Foods Company (NASDAQ: SMPL) What: Securities fraud class action lawsuit filed Class Period: October 24, 2024 through April 8, 2026 Deadline to Seek Lead Plaintiff...
- Kikkoman Foods, Inc.KIKKOMAN FOODS, INC. OFFICIALLY OPENS THIRD U.S. PRODUCTION FACILITY IN JEFFERSON, WISCONSINNew state-of-the-art brewing plant expands North American production capacity and fuels local job growth — Kikkoman Foods, Inc. (KFI), the U.S. manufacturing arm of the world's leading soy sauce brand, today celebrated the official grand...
- HF Foods Group Announces Termination of At-The-Market Equity Offering ProgramHF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading distributor of international foodservice solutions to Asian restaurants and other businesses across the United States and Canada, today announced that it has terminated the Sales Agreement among the Company, D.A. Davidson & Co. and Roth Capital Partners, LLC, dated September 25, 2025 (the "Sales Agreement") and the At-The-Market (“ATM”) equity offering program it established on September 25, 2025, under which the Company could sell shares of its common stock for aggregate gross proceeds of up to $100 million. The termination is effective as of September 24, 2026.